XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.2

Revenue (Tables)

6 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

Schedule of Total Revenue by Product and by U.S versus Rest of World

The following table presents detail regarding the composition of the Company’s total revenue by category and by U.S. versus rest of world (“RoW”):

			Three months ended June 30,
			2021																		2020
(in millions)			U.S.						RoW						Total						U.S.						RoW						Total
Molecular diagnostic revenues:
Hereditary Cancer			$	73.8					$	12.2					$	86.0					$	34.9					$	5.0					$	39.9
Tumor Profiling			18.1						11.1						29.2						8.6						1.9						10.5
Prenatal			29.2						0.2						29.4						16.5						0.1						16.6
Pharmacogenomics			22.6						—						22.6						8.5						—						8.5
Autoimmune			10.2						—						10.2						7.3						—						7.3
Other			0.2						1.1						1.3						0.5						—						0.5
Total molecular diagnostic revenue			154.1						24.6						178.7						76.3						7.0						83.3
Pharmaceutical and clinical service revenue			10.7						—						10.7						9.9						—						9.9
Total revenue			$	164.8					$	24.6					$	189.4					$	86.2					$	7.0					$	93.2
			Six months ended June 30,
			2021																		2020
(in millions)			U.S.						RoW						Total						U.S.						RoW						Total
Molecular diagnostic revenues:
Hereditary Cancer			$	138.9					$	23.2					$	162.1					$	116.2					$	8.9					$	125.1
Tumor Profiling			42.3						17.9						60.2						19.3						4.9						24.2
Prenatal			52.8						0.3						53.1						36.7						0.2						36.9
Pharmacogenomics			40.2						—						40.2						28.9						—						28.9
Autoimmune			20.9						—						20.9						17.7						—						17.7
Other			0.2						1.6						1.8						1.0						—						1.0
Total molecular diagnostic revenue			295.3						43.0						338.3						219.8						14.0						233.8
Pharmaceutical and clinical service revenue			24.2						—						24.2						19.5						3.9						23.4
Total revenue			$	319.5					$	43.0					$	362.5					$	239.3					$	17.9					$	257.2

Reconciliation of Deferred Revenue Balances

A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:

			Six months ended June 30,
(in millions)			2021						2020
Deferred revenue - beginning balance			$	32.7					$	3.6
Revenue recognized			(15.5)						(6.1)
Prepayments			6.3						35.3
Held for sale reclassification			(0.9)						—
Deferred revenue - ending balance			$	22.6					$	32.8

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration